SelectQuote (SLQT) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
The 2025 Annual Meeting will be held virtually on November 11, 2025, with voting on director elections, auditor ratification, and executive compensation.
Only shareholders of record as of September 23, 2025, are eligible to vote; a majority of shares constitutes a quorum.
The Board recommends voting FOR all proposals, including the election of two Class III directors, ratification of Deloitte & Touche LLP, and approval of executive compensation.
Voting can be done online, by phone, mail, or during the meeting; votes can be changed prior to the meeting.
Voting matters and shareholder proposals
Proposal 1: Elect two Class III directors (Denise L. Devine and Donald L. Hawks III) for terms expiring in 2028.
Proposal 2: Ratify Deloitte & Touche LLP as independent auditor for fiscal year ending June 30, 2026.
Proposal 3: Approve, on a non-binding basis, the compensation of named executive officers (say-on-pay).
Board recommends FOR all proposals; voting results will be disclosed in a Form 8-K.
Board of directors and corporate governance
Board consists of eight directors, with a majority qualifying as independent under NYSE standards.
Board is classified into three staggered classes; separation of CEO and Chairman roles for effective oversight.
Four standing committees: Audit, Compensation and Talent Development, Nominating and Corporate Governance, and Healthcare Oversight.
Regular executive sessions held without management; robust stockholder engagement and communication processes.
Directors are subject to stock ownership guidelines and a code of business conduct and ethics.
Latest events from SelectQuote
- Diversified insurance and healthcare platform achieves strong growth and operational efficiency.SLQT
Investor presentation - Q3 FY2026 revenue up 6% to $430.9M, net income $40.2M, with robust segment growth and outlook.SLQT
Q3 2026 - Revenue up 12% to $537.1M, net income $69.3M, and guidance cut by $40M amid external headwinds.SLQT
Q2 2026 - Board recommends approval of all proposals, highlighting governance and pay-for-performance.SLQT
Proxy Filing - Virtual annual meeting to vote on directors, auditor, and executive pay, with board support.SLQT
Proxy Filing - All proposals passed, including director elections and auditor ratification, with no shareholder questions.SLQT
AGM 2025 - FY2024 results surpassed expectations, with robust growth in revenue and profitability.SLQT
Q4 2024 - Revenue up 26% with strong pharmacy growth; $100M securitization boosts capital flexibility.SLQT
Q1 2025 - Q2 revenue up 19% to $481.1M, net income $53.2M, $350M equity investment secured.SLQT
Q2 2025